These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3045033)

  • 1. The placebo effect during a double blind trial of recombinant alpha 2 interferon in multiple sclerosis patients: immunological and clinical findings.
    Hirsch RL; Johnson KP; Camenga DL
    Int J Neurosci; 1988 Apr; 39(3-4):189-96. PubMed ID: 3045033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer cell activity in multiple sclerosis patients treated with recombinant interferon-alpha 2.
    Hirsch RL; Johnson KP
    Clin Immunol Immunopathol; 1985 Nov; 37(2):236-44. PubMed ID: 3899434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial of natural alpha interferon in multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CJ; Kamin-Lewis RM; Johnson KP
    Ann N Y Acad Sci; 1984; 436():382-8. PubMed ID: 6398020
    [No Abstract]   [Full Text] [Related]  

  • 4. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.
    Camenga DL; Johnson KP; Alter M; Engelhardt CD; Fishman PS; Greenstein JI; Haley AS; Hirsch RL; Kleiner JE; Kofie VY
    Arch Neurol; 1986 Dec; 43(12):1239-46. PubMed ID: 3535752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.
    Kastrukoff LF; Morgan NG; Zecchini D; White R; Petkau AJ; Satoh J; Paty DW
    Neurology; 1999 Jan; 52(2):351-9. PubMed ID: 9932956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic alpha-interferon therapy of multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CK; Kamin-Lewis RM; Johnson KP
    Neurology; 1984 Oct; 34(10):1273-9. PubMed ID: 6384817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer cell activity in patients with multiple sclerosis given alpha interferon.
    Rice GP; Casali P; Merigan TC; Oldstone MB
    Ann Neurol; 1983 Sep; 14(3):333-8. PubMed ID: 6638954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of recombinant alpha 2-interferon on defective natural killer cell activity in multiple sclerosis.
    Hirsch RL; Johnson KP
    Neurology; 1985 Apr; 35(4):597-600. PubMed ID: 3982654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group.
    J Neurol Neurosurg Psychiatry; 1989 May; 52(5):566-74. PubMed ID: 2659737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
    Clerico M; Faggiano F; Palace J; Rice G; Tintorè M; Durelli L
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005278. PubMed ID: 18425915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid interferon.
    Kastrukoff LF; Morgan NG; Aziz TM; Zecchini D; Berkowitz J; Paty DW
    J Neuroimmunol; 1988 Nov; 20(1):15-23. PubMed ID: 3183034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a.
    Nortvedt MW; Riise T; Myhr KM; Nyland HI; Hanestad BR
    Mult Scler; 1999 Oct; 5(5):317-22. PubMed ID: 10516774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interferon-alpha2b recombinant improved the cognitive dysfunction in patients with relapsing remitting multiple sclerosis].
    Cabrera-Gómez JA; Echazábal-Santana N; Porrero-Martín P; Valenzuela-Silva C; Rodríguez CA; Fuentes-Suárez I; Pérez-Ruiz L; Ramos-Cedeño AM; Cabrera-Núñez JA;
    Rev Neurol; 2003 Aug 1-15; 37(3):214-20. PubMed ID: 12938052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha interferon clinical trial for multiple sclerosis: design considerations.
    Alter M; Greenstein J; Camenga D; LaRue L
    Neuroepidemiology; 1987; 6(1-2):85-92. PubMed ID: 3306431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term recombinant interferon alpha treatment in MS with special emphasis to side effects.
    Durelli L; Bongioanni MR; Ferrero B; Imperiale D; Verdun E; Oggero A; Gentile E; Bradac GB; Bergui M; Bergamini L; Bergamasco B
    Mult Scler; 1996 Jul; 1(6):366-71. PubMed ID: 9345419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic interferon therapy of multiple sclerosis: the pros.
    Knobler RL
    Neurology; 1988 Jul; 38(7 Suppl 2):58-61. PubMed ID: 3133575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation.
    Kastrukoff LF; Oger JJ; Hashimoto SA; Sacks SL; Li DK; Palmer MR; Koopmans RA; Petkau AJ; Berkowitz J; Paty DW
    Neurology; 1990 Mar; 40(3 Pt 1):479-86. PubMed ID: 2179764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis.
    Bongioanni MR; Durelli L; Ferrero B; Imperiale D; Oggero A; Verdun E; Aimo G; Pagni R; Geuna M; Bergamasco B
    J Neurol Sci; 1996 Nov; 143(1-2):91-9. PubMed ID: 8981304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.